Newsroom
BC Partners has been named winner of the ‘Benelux Deal of the Year’ award at the Real Deals Private Equity Awards 2026, recognising the successful partnership with Synthon.
The award highlights Synthon’s strong organic growth, capex‑led value creation and disciplined strategic execution, including margin improvement, commercial enhancements and international expansion achieved during BC Partners’ ownership.
Zydus Lifesciences Ltd. (including its subsidiaries and affiliates), a global innovation-driven healthcare company, announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Synthon BV of the Netherlands for Ozanimod Capsules (a generic version of ZEPOSIA®) for the U.S. market. Synthon has a pending abbreviated new drug application in the United States, seeking approval for Ozanimod Capsules indicated for relapsing forms of multiple sclerosis.
Nijmegen, 16th June 2025 – Today, Synthon (the “Company”) a leading platform specialized in developing, manufacturing, and out-licensing complex generic medicines, announced an investment from Private Equity at Goldman Sachs Alternatives. This represents the acquisition of a majority stake in the Company from funds advised by BC Partners, who will continue to own a significant stake in the Company.
